Alkem Laboratories CFO Nitin Agrawal resigns, exits 30 Sept 2026

CFO resignedKey managerial personnel resignedManagement Changes View source PDF Explain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.9%Reaction day

₹5413.00

prior close

₹5404.00

announcement price

In-mkt

timing

Nifty Midcap 150market-2.0%+0.1% vs market

Pharmaceuticals peers, median of 172sector-1.0%-0.9% vs sector

On the reaction day the stock moved 0.1 pts more than Nifty Midcap 150 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.2

10m

-1.6

15m

-1.4

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.9-2.0+0.1-1.0-0.9

Next day

-2.6-2.1-0.4-0.8-1.8

-4.4-3.7-0.7-1.8-2.6

-3.0-4.7+1.7-1.4-1.7

-4.6-4.6+0.0-2.5-2.1

-3.6-5.6+2.0-3.0-0.6

-2.8-4.1+1.3-2.8-0.0

15d

-6.7-5.2-1.5-5.6-1.1

-7.1-9.2+2.2-9.7+2.6

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 172Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alkem Laboratories announced that its Chief Financial Officer and Key Managerial Personnel, Mr. Nitin Agrawal, has resigned to pursue new professional opportunities. He will cease to hold the Senior Management position effective 30 September 2026, serving about a two month notice period to ensure a smooth handover. His resignation was tendered on 30 July 2026. During his tenure he led strategic moves including the MedTech business build up, Adroit and Bombay Ortho acquisitions, Saudi joint venture formation, and Alkem Wellness creation.

Likely market impact

CFO exit creates short term leadership transition risk. Watch for timely successor appointment; stock may react to succession uncertainty.